167 related articles for article (PubMed ID: 10665788)
1. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy.
Rudat V; Dietz A; Schramm O; Conradt C; Maier H; Flentje M; Wannenmacher M
Radiother Oncol; 1999 Nov; 53(2):119-25. PubMed ID: 10665788
[TBL] [Abstract][Full Text] [Related]
2. [Simultaneous radiochemotherapy with carboplatin in patients with inoperable advanced stage III and IV head and neck tumors].
Mücke R; Blynow M; Ziegler PG; Libera T; Kundt G; Dommerich S; Kramp B; Fietkau R
Strahlenther Onkol; 1999 May; 175(5):213-7. PubMed ID: 10356610
[TBL] [Abstract][Full Text] [Related]
3. Acute and late toxicity, tumour control and intrinsic radiosensitivity of primary fibroblasts in vitro of patients with advanced head and neck cancer after concomitant boost radiochemotherapy.
Rudat V; Dietz A; Nollert J; Conradt C; Weber KJ; Flentje M; Wannenmacher M
Radiother Oncol; 1999 Dec; 53(3):233-45. PubMed ID: 10660204
[TBL] [Abstract][Full Text] [Related]
4. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation.
Johnson CR; Khandelwal SR; Schmidt-Ullrich RK; Ravalese J; Wazer DE
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):635-41. PubMed ID: 7790249
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy.
Dietz A; Rudat V; Conradt C; Weidauer H; Ho A; Moehler T
Head Neck; 2000 Oct; 22(7):666-73. PubMed ID: 11002321
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors.
Schäfer U; Micke O; Müller SB; Schüller P; Willich N
Strahlenther Onkol; 2003 Aug; 179(8):527-34. PubMed ID: 14509951
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer.
Kurek R; Kalogera-Fountzila A; Muskalla K; Dafni U; Schnabel T; Kober B; Röddiger S; Martin T; Fountzilas G; Zamboglou N
Strahlenther Onkol; 2003 May; 179(5):292-7. PubMed ID: 12740655
[TBL] [Abstract][Full Text] [Related]
8. Role of concomitant chemoradiation in locally advanced head and neck cancers.
Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of cell-cycle regulatory proteins for outcome after primary radiochemotherapy in patients with advanced head and neck cancer].
Haas S; Bosch FX; Klein-Kühne W; Nollert J; Rudat V; Conradt C; Dietz A
HNO; 1999 Sep; 47(9):777-86. PubMed ID: 10525606
[TBL] [Abstract][Full Text] [Related]
10. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
[TBL] [Abstract][Full Text] [Related]
11. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer.
Nordsmark M; Overgaard J
Acta Oncol; 2004; 43(4):396-403. PubMed ID: 15303502
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy.
Rades D; Stoehr M; Kazic N; Hakim SG; Walz A; Schild SE; Dunst J
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1108-14. PubMed ID: 17905528
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiochemotherapy for head and neck tumors.
Reichel O; Panzer M; Wimmer C; Dühmke E; Kastenbauer E; Suckfüll M
Eur Arch Otorhinolaryngol; 2003 May; 260(5):248-53. PubMed ID: 12750913
[TBL] [Abstract][Full Text] [Related]
14. [Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
Dietz A; Rudat V; Nollert J; Flentje M; Maiei H; Wannenmacher M; Weidauer H
Laryngorhinootologie; 1996 Dec; 75(12):745-53. PubMed ID: 9081280
[TBL] [Abstract][Full Text] [Related]
15. Accelerated superfractionated radiotherapy with concomitant boost for locally advanced head-and-neck squamous cell carcinomas.
Morris MM; Schmidt-Ullrich RK; DiNardo L; Manning MA; Silverman L; Clay L; Johnson CR; Amir C
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):918-28. PubMed ID: 11958884
[TBL] [Abstract][Full Text] [Related]
16. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
[TBL] [Abstract][Full Text] [Related]
17. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin.
Rudat V; Eckel H; Volling P; Schröder M; Staar S; Wallner F; Wannenmacher M; Dietz A
Radiother Oncol; 2008 Oct; 89(1):33-7. PubMed ID: 18621428
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
[TBL] [Abstract][Full Text] [Related]
20. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
